25.28
-0.29 (-1.13%)
| Penutupan Terdahulu | 25.57 |
| Buka | 25.47 |
| Jumlah Dagangan | 1,947,584 |
| Purata Dagangan (3B) | 2,390,107 |
| Modal Pasaran | 4,034,583,040 |
| Harga / Jualan (P/S) | 14.05 |
| Harga / Buku (P/B) | 31.15 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 4 Nov 2026 |
| Margin Keuntungan | -74.84% |
| Margin Operasi (TTM) | -56.45% |
| EPS Cair (TTM) | -0.950 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 25.20% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 115.90% |
| Nisbah Semasa (MRQ) | 2.92 |
| Aliran Tunai Operasi (OCF TTM) | -85.34 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -21.40 M |
| Pulangan Atas Aset (ROA TTM) | -15.05% |
| Pulangan Atas Ekuiti (ROE TTM) | -61.03% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Diagnostics & Research (US) | Bercampur | Menaik |
| Diagnostics & Research (Global) | Bercampur | Menaik | |
| Stok | Adaptive Biotechnologies Corpor | Bercampur | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | NA |
| Aktiviti Orang Dalam | -3.5 |
| Volatiliti Harga | -3.5 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | -0.5 |
| Penilaian Relatif | NA |
| Kesihatan Kewangan | NA |
| AI Insight | NA |
| Purata | -1.25 |
|
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is a test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers. The company has two operating segments: Minimal Residual Disease and Immune Medicine. The company generates the majority of its revenue from the Minimal Residual Disease segment. |
|
| Sektor | Healthcare |
| Industri | Diagnostics & Research |
| Gaya Pelaburan | Small Core |
| % Dimiliki oleh Orang Dalam | 2.35% |
| % Dimiliki oleh Institusi | 98.36% |
Tiada data dalam julat masa ini.
| Nama | Purata Belian ($) | Purata Jualan ($) | Jumlah Net | Jumlah Nilai Bersih ($) |
|---|---|---|---|---|
| BOBULSKY SUSAN | - | 26.90 | -6,444 | -173,344 |
| RUBINSTEIN JULIE | - | 27.49 | -59,405 | -1,633,162 |
| Jumlah Keseluruhan Kuantiti Bersih | -65,849 | |||
| Jumlah Keseluruhan Nilai Bersih ($) | -1,806,506 | |||
| Purata Pembelian Keseluruhan ($) | - | |||
| Purata Jualan Keseluruhan ($) | 27.39 | |||
| Nama | Pemegang | Tarikh | Jenis | Kuantiti | Harga | Nilai ($) |
|---|---|---|---|---|---|---|
| RUBINSTEIN JULIE | Pegawai | 08 Oct 2026 | Jual automatik (-) | 11,881 | 26.09 | 309,975 |
| RUBINSTEIN JULIE | Pegawai | 08 Oct 2026 | Pelaksanaan pilihan | 11,881 | - | - |
| RUBINSTEIN JULIE | Pegawai | 07 Oct 2026 | Jual automatik (-) | 11,881 | 26.28 | 312,233 |
| RUBINSTEIN JULIE | Pegawai | 07 Oct 2026 | Pelaksanaan pilihan | 11,881 | - | - |
| BOBULSKY SUSAN | Pegawai | 06 Oct 2026 | Jual automatik (-) | 6,444 | 26.90 | 173,344 |
| RUBINSTEIN JULIE | Pegawai | 06 Oct 2026 | Jual automatik (-) | 11,881 | 26.90 | 319,599 |
| RUBINSTEIN JULIE | Pegawai | 06 Oct 2026 | Pelaksanaan pilihan | 11,881 | - | - |
| RUBINSTEIN JULIE | Pegawai | 05 Oct 2026 | Jual automatik (-) | 11,881 | 29.84 | 354,529 |
| RUBINSTEIN JULIE | Pegawai | 05 Oct 2026 | Pelaksanaan pilihan | 11,881 | - | - |
| RUBINSTEIN JULIE | Pegawai | 02 Oct 2026 | Jual automatik (-) | 11,881 | 28.35 | 336,826 |
| RUBINSTEIN JULIE | Pegawai | 02 Oct 2026 | Pelaksanaan pilihan | 11,881 | - | - |
| Papar semua | ||||||
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |